Home / Community / News / News

News

01/28/2016 - 7:35am

The use of anesthesia raises special risks to DM patients, which include heightened sensitivity to sedatives and analgesics. Serious complications are most common in the post-anesthesia period when risk of aspiration and other complications are increased. 

MDF has published two versions of its 2016 Anesthesia Guidelines:

  • Click here for a handy, one-page summary of the anesthesia guidelines to share with your clinician and anesthesiologist. 
  • Click here for the complete "Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient".

New to DM? For here for more information.

 

01/14/2016 - 12:32pm

Word came from the FDA on January 14th that it would not approve the new drug application for "Kendrisa,"  Biomarin's antisense-oligo based drug for Duchenne muscular dystrophy.

12/02/2015 - 11:36am

Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.

11/16/2015 - 2:44pm

The Myotonic Dystrophy Foundation partnered with Silicon Valley Research Group to develop a survey to better understand how people with DM weigh the benefits of new treatments again the risks. 

03/25/2015 - 11:40am

Researchers and medical professionals from Europe, Canada and the USA gathered recently for a workshop in Europe to identify the main respiratory issues and best respiratory treatments for people with DM.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.